Upregulation of miR21 and repression of Grhl3 by leptin mediates sinusoidal endothelial injury in experimental nonalcoholic steatohepatitis

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Pourhoseini, Sahar ^a   Seth, Ratanesh Kumar ^a   Das, Suvarthi ^a   Dattaroy, Diptadip ^a   Kadiiska, Maria B ^b   Xie, Guanhua ^c   Michelotti, Gregory A ^c   Nagarkatti, Mitzi ^d   Diehl, Anna Mae ^c   Chatterjee, Saurabh ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Nalt Inst of Environ Health Sci   (United States)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN; LEPTIN RECEPTOR; MICRORNA 21; VASCULOTROPIN RECEPTOR 2; DNA BINDING PROTEIN; GRHL3 PROTEIN, MOUSE; MICRORNA; MIRN-21 MICRORNA, MOUSE; TRANSCRIPTION FACTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; E SELECTIN GENE; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENZYME PHOSPHORYLATION; GENE; GENE FUNCTION; GENE REPRESSION; GRHL3 GENE; HYPERLEPTINEMIA; ICAM 1 GENE; IN VIVO STUDY; KUPFFER CELL; LEPTIN GENE; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINUSOIDAL ENDOTHELIUM INJURY; STELLATE CELL; UPREGULATION; VEGFR 2 GENE; ANIMAL; COMPLICATION; ENDOTHELIUM; GENE EXPRESSION REGULATION; GENETICS; LIVER; METABOLISM; PATHOPHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

MUS; MUS MUSCULUS; RODENTIA;

ANIMALS; BLOTTING, WESTERN; DNA-BINDING PROTEINS; ENDOTHELIUM; GENE EXPRESSION REGULATION; LEPTIN; LIVER; MICE; MICE, TRANSGENIC; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS;

EID: 84922733642     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116780     Document Type: Article

References (55)

1. Michelotti GA, Machado MV, Diehl AM (2013) NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 10: 656-665.
2. Bohinc BN, Diehl AM (2012) Mechanisms of disease progression in NASH: new paradigms. Clin Liver Dis 16: 549-565. PMID: 22824480
3. Jou J, Choi SS, Diehl AM (2008) Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 28: 370-379. PMID: 18956293
4. Tilg H, Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52: 1836-1846. doi: 10.1002/hep.24001 PMID: 21038418
5. Farrell GC, Teoh NC, McCuskey RS (2008) Hepatic microcirculation in fatty liver disease. Anat Rec (Hoboken) 291: 684-692. PMID: 18484615
6. Muller WA (2011) Mechanisms of leukocyte transendothelial migration. Annu Rev Pathol 6: 323-344.
7. Rafiee P, Stein DJ, Nelson VM, Otterson MF, Shaker R, et al. (2010) Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC). Am J Physiol Gastrointest Liver Physiol 298: G167-176. doi: 10.1152/ajpgi.00385.2009 PMID: 19926820
8. Ip E, Farrell G, Hall P, Robertson G, Leclercq I (2004) Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 39: 1286-1296. PMID: 15122757
9. Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, et al. (2001) Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 34: 288-297. PMID: 11481614
10. Krawczyk K, Szczesniak P, Kumor A, Jasinska A, Omulecka A, et al. (2009) Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH). J Physiol Pharmacol 60 Suppl 3: 71-75. PMID: 19996485
11. Li Z, Lin H, Yang S, Diehl AM (2002) Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. Gastroenterology 123: 1304-1310. PMID: 12360490
12. Wang J, Leclercq I, Brymora JM, Xu N, Ramezani-Moghadam M, et al. (2009) Kupffer cells mediate leptin- induced liver fibrosis. Gastroenterology 137: 713-723. doi: 10.1053/j.gastro.2009.04.011 PMID: 19375424
13. De Minicis S, Seki E, Oesterreicher C, Schnabl B, Schwabe RF, et al. (2008) Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells. Hepatology 48: 2016-2026. doi: 10.1002/hep.22560 PMID: 19025999
14. Chatterjee S, Ganini D, Tokar EJ, Kumar A, Das S, et al. (2012) Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation in experimental nonalcoholic steatohepatitis. J Hepatol.
15. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA (2002) Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 35: 762-771. PMID: 11915021
16. Saxena NK, Saliba G, Floyd JJ, Anania FA (2003) Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells. J Cell Biochem 89: 311-320. PMID: 12704794
17. Saxena NK, Titus MA, Ding X, Floyd J, Srinivasan S, et al. (2004) Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. FASEB J 18: 1612-1614. PMID: 15319373
18. Kitade M, Yoshiji H, Kojima H, Ikenaka Y, Noguchi R, et al. (2006) Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 44: 983-991. PMID: 17006938
19. Korda M, Kubant R, Patton S, Malinski T (2008) Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol 295: H1514-1521.
20. Pasarin M, La Mura V, Gracia-Sancho J, Garcia-Caldero H, Rodriguez-Vilarrupla A, et al. (2012) Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. PLoS One 7: e32785. doi: 10.1371/journal.pone.0032785 PMID: 22509248
21. Musso G, Gambino R, Cassader M (2010) Emerging molecular targets for the treatment of nonalcoholic fatty liver disease. Annu Rev Med 61: 375-392. PMID: 20059344
22. Cheung O, Sanyal AJ (2010) Role of microRNAs in non-alcoholic steatohepatitis. Curr Pharm Des 16: 1952-1957.
23. Kerr TA, Korenblat KM, Davidson NO (2011) MicroRNAs and liver disease. Transl Res 157: 241-252.
24. Rottiers V, Naar AM (2012) MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 13: 239-250.
25. Pogribny IP, Beland FA (2013) Role of microRNAs in the regulation of drug metabolism and disposition genes in diabetes and liver disease. Expert Opin Drug Metab Toxicol 9: 713-724. doi: 10.1517/ 17425255.2013.783817 PMID: 23565851
26. Ceccarelli S, Panera N, Gnani D, Nobili V (2013) Dual Role of MicroRNAs in NAFLD. Int J Mol Sci 14: 8437-8455. doi: 10.3390/ijms14048437 PMID: 23594995
27. Mukhopadhyay P, Mukherjee S, Ahsan K, Bagchi A, Pacher P, et al. (2010) Restoration of altered microRNA expression in the ischemic heart with resveratrol. PLoS One 5: e15705. doi: 10.1371/ journal.pone.0015705 PMID: 21203465
28. Noetel A, Kwiecinski M, Elfimova N, Huang J, Odenthal M (2012) microRNA are Central Players in Antiand Profibrotic Gene Regulation during Liver Fibrosis. Front Physiol 3: 49. doi: 10.3389/fphys.2012. 00049 PMID: 22457651
29. Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, et al. (2013) Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 424C: 99-103. doi: 10.1016/j.cca.2013.05.021 PMID: 23727030
30. Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, et al. (2009) Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 50: 1152-1161. doi: 10.1002/hep.23100 PMID: 19711427
31. Lukosz M, Mlynek A, Czypiorski P, Altschmied J, Haendeler J (2011) The transcription factor Grainyhead like 3 (GRHL3) affects endothelial cell apoptosis and migration in a NO-dependent manner. Biochem Biophys Res Commun 412: 648-653. doi: 10.1016/j.bbrc.2011.08.018 PMID: 21856281
32. Darido C, Georgy SR, Wilanowski T, Dworkin S, Auden A, et al. (2011) Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis. Cancer Cell 20: 635-648. doi: 10.1016/j.ccr.2011.10.014 PMID: 22094257
33. Xie G, Choi SS, Syn WK, Michelotti GA, Swiderska M, et al. (2013) Hedgehog signalling regulates liver sinusoidal endothelial cell capillarisation. Gut 62: 299-309. doi: 10.1136/gutjnl-2011-301494 PMID: 22362915
34. Cayon A, Crespo J, Mayorga M, Guerra A, Pons-Romero F (2006) Increased expression of Ob-Rb and its relationship with the overexpression of TGF-beta1 and the stage of fibrosis in patients with nonalcoholic steatohepatitis. Liver Int 26: 1065-1071. PMID: 17032406
35. Ikejima K, Okumura K, Lang T, Honda H, Abe W, et al. (2005) The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol Res 33: 151-154. PMID: 16198623
36. Imajo K, Fujita K, Yoneda M, Nozaki Y, Ogawa Y, et al. (2012) Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab 16: 44-54. doi: 10.1016/j.cmet.2012.05.012 PMID: 22768838
37. Seth RK, Das S, Kumar A, Chanda A, Kadiiska MB, et al. (2014) CYP2E1-dependent and leptin-mediated hepatic CD57 expression on CD8+ T cells aid progression of environment-linked nonalcoholic steatohepatitis. Toxicol Appl Pharmacol 274: 42-54. doi: 10.1016/j.taap.2013.10.029 PMID: 24211274
38. Das S, Kumar A, Seth RK, Tokar EJ, Kadiiska MB, et al. (2013) Proinflammatory adipokine leptin mediates disinfection byproduct bromodichloromethane-induced early steatohepatitic injury in obesity. Toxicol Appl Pharmacol.
39. Lawrie CH (2013) MicroRNAs in hematological malignancies. Blood Rev 27: 143-154.
40. Alisi A, Da Sacco L, Bruscalupi G, Piemonte F, Panera N, et al. (2011) Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab Invest 91: 283-293. doi: 10.1038/labinvest.2010.166 PMID: 20956972
41. Matsuda S, Kobayashi M, Kitagishi Y (2013) Roles for PI3K/AKT/PTEN Pathway in Cell Signaling of Nonalcoholic Fatty Liver Disease. ISRN Endocrinol 2013: 472432. doi: 10.1155/2013/472432 PMID: 23431468
42. Pasarin M, Abraldes JG, Rodriguez-Vilarrupla A, La Mura V, Garcia-Pagan JC, et al. (2011) Insulin resistance and liver microcirculation in a rat model of early NAFLD. J Hepatol 55: 1095-1102. doi: 10. 1016/j.jhep.2011.01.053 PMID: 21356259
43. Quinn SR, O'Neill LA (2011) A trio of microRNAs that control Toll-like receptor signalling. Int Immunol 23: 421-425. doi: 10.1093/intimm/dxr034 PMID: 21652514
44. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O'Leary JJ, et al. (2010) Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 11: 141-147. doi: 10.1038/ni.1828 PMID: 19946272
45. Copaci I, Micu L, Voiculescu M (2006) The role of cytokines in non-alcoholic steatohepatitis. A review. J Gastrointestin Liver Dis 15: 363-373. PMID: 17205149
46. Procaccini C, Galgani M, De Rosa V, Carbone F, La Rocca C, et al. (2010) Leptin: the prototypic adipocytokine and its role in NAFLD. Curr Pharm Des 16: 1902-1912. PMID: 20370676
47. Zhang Y, Scarpace PJ (2006) The role of leptin in leptin resistance and obesity. Physiol Behav 88: 249-256.
48. Kida K, Nakajima M, Mohri T, Oda Y, Takagi S, et al. (2011) PPARalpha is regulated by miR-21 and miR-27b in human liver. Pharm Res 28: 2467-2476. doi: 10.1007/s11095-011-0473-y PMID: 21562928
49. Ng R, Song G, Roll GR, Frandsen NM, Willenbring H (2012) A microRNA-21 surge facilitates rapid cyclin D1 translation and cell cycle progression in mouse liver regeneration. J Clin Invest 122: 1097-1108. doi: 10.1172/JCI46039 PMID: 22326957
50. Fleming I, Busse R (1999) Signal transduction of eNOS activation. Cardiovasc Res 43: 532-541.
51. Iwakiri Y (2012) Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver Int 32: 199-213. PMID: 21745318
52. Bosch J, Abraldes JG, Fernandez M, Garcia-Pagan JC (2010) Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol 53: 558-567. PMID: 20561700
53. Nakagawa T (2007) Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol 292: F1665-1672. PMID: 17545302
54. Paulus P, Jennewein C, Zacharowski K (2011) Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis? Biomarkers 16 Suppl 1: S11-21. doi: 10.3109/ 1354750X.2011.587893 PMID: 21707440
55. Radisavljevic Z, Avraham H, Avraham S (2000) Vascular endothelial growth factor up-regulates ICAM- 1 expression via the phosphatidylinositol 3 OH-kinase/AKT/Nitric oxide pathway and modulates migration of brain microvascular endothelial cells. J Biol Chem 275: 20770-20774. PMID: 10787417